medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2024-27-55-59medalphabet-4061Research ArticleСтатьиНейроэндокринный рак предстательной железы (клинический случай)Neuroendocrine prostate cancer (clinical case)https://orcid.org/0009-0007-8377-9601ХакимовГ. А.KhakimovG A.

Хакимов Голиб Абдуллаевич, д.м.н., проф., зав. кафедрой детской онкологии, паллиативной помощи; директор

Ташкент; Москва

Khakimov Golib A., DM Sci (habil.), prof., head of Dept of Pediatric Oncology, Palliative Care; director

Tashkent

golib_khakimov@mail.ruhttps://orcid.org/0000-0002-4970-5429ХакимоваГ. Г.KhakimovaG. G.

Хакимова Гулноз Голибовна, к.м.н., доцент кафедры детской онкологии, паллиативной помощи; врач-онколог; стажер кафедры онкологии, радиотерапии и реконструктивной хирургии

Ташкент; Москва

Khakimova Gulnoz G., PhD Med, associate prof. at Dept of Pediatric Oncology, Palliative Care; oncologist; intern of Dept of Oncology, Radiotherapy and Reconstructive Surgery

Tashkent; Moscow

hgg_doc@mail.ruhttps://orcid.org/0009-0005-9984-6907ДаллоС. Ф.DalloS. F.

Далло Сальва Фаековна, ассистент кафедры онкологии, онкогематологии, радиационной онкологии

Ташкент

Dallo Salva F., assistant at Dept of Oncology, Oncohematology, Radiation Oncology

Tashkent

salva.dallo_1996@icloud.comhttps://orcid.org/0000-0002-9491-0413ХакимоваШ. Г.KhakimovaSh. G.

Хакимова Шахноз Голибовна, д.м.н., доцент кафедры детской онкологии, паллиативной помощи; врач-онколог отделения онкологии и реконструктивной хирургии молочной железы и кожи

Ташкент; Москва

Khakimova Shakhnoz G., DM Sci (habil.), associate prof. at Dept of Pediatric Oncology, palliative care; oncologist

Tashkent; Moscow

shahnoz_hakimova@mail.ruhttps://orcid.org/0009-0006-7480-1689ХакимовА. М.KhakimovA. M.

Хакимов Абдугияс Мейлиевич, врач-онколог

Ташкент

Khakimov Abdugiyaz M., oncologist

Tashkent

khakimov_a@mail.ruТашкентский педиатрический медицинский институт; Ташкентский городской филиал Республиканского специализированного научно-практического медицинского центра онкологии и радиологииУзбекистанTashkent Pediatric Medical Institute; Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and RadiologyUzbekistanТашкентский педиатрический медицинский институт; Ташкентский городской Республиканского специализированного научно-практического медицинского центра онкологии и радиологии; Институт клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)УзбекистанTashkent Pediatric Medical Institute; Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology; 4 Moscow Institute of Clinical Medicine N.V. Sklifosovsky, I.M. Sechenov First Moscow State Medical University (Sechenov University)UzbekistanТашкентский педиатрический медицинский институтУзбекистанTashkent Pediatric Medical InstituteUzbekistanТашкентский педиатрический медицинский институт; Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии»УзбекистанTashkent Pediatric Medical Institute; Moscow Research Oncology Institute P.A. Herzen – branch of the National Medical Research Center of RadiologyUzbekistanТашкентский городской филиал Республиканского специализированного научно-практического медицинского центра онкологии и радиологииУзбекистанTashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and RadiologyUzbekistan202416122024027Диагностика и онкотерапия (3)5559Copyright © Хакимов Г.А., Хакимова Г.Г., Далло С.Ф., Хакимова Ш.Г., Хакимов А.М., 20242024Хакимов Г.А., Хакимова Г.Г., Далло С.Ф., Хакимова Ш.Г., Хакимов А.М.Khakimov G.A., Khakimova G.G., Dallo S.F., Khakimova S.G., Khakimov A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4061

Нейроэндокринный рак предстательной железы представляет собой редкий и агрессивный вариант рака с неблагоприятным прогнозом. Этот вид рака часто диагностируется на поздних стадиях и характеризуется быстрой резистентностью к стандартным терапевтическим методам. С учетом низко встречаемости это патологии приводится описание низкодифференцированного нероэндокринного (мелкоклеточного) рака предстательной железы с кране агрессивным течением.

Neuroendocrine prostate cancer is a rare and aggressive cancer with a poor prognosis. This type of cancer is often diagnosed at an advanced stage and exhibits rapid resistance to standard therapeutic methods. Taking into account the low occurrence of this phenomenon, a description of poorly differentiated neuroendocrine (small cell) prostate cancer with extremely aggressive forms is given.

нероэндокринны ракпредстательная железагормонорезистентностьneuroendocrine cancercastration-resistant cancerprostatehormone resistanceReferencesAggarwal R., Zhang T., Small E.J., Armstrong A. J. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J. Natl. Compr. Canc. Netw. 2014; 12 (5): 719–26. DOI: 10.6004/jnccn.2014.0073Aggarwal R., Zhang T., Small E.J., Armstrong A. J. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J. Natl. Compr. Canc. Netw. 2014; 12 (5): 719–26. DOI: 10.6004/jnccn.2014.0073Hirano D., Okada Y., Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 2004; 45 (5): 586–92. DOI: 10.1016/j.eururo.2003.11.032Hirano D., Okada Y., Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 2004; 45 (5): 586–92. DOI: 10.1016/j.eururo.2003.11.032Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018; 36 (24): 2492–503. DOI: 10.1200/JCO.2017.77.6880Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018; 36 (24): 2492–503. DOI: 10.1200/JCO.2017.77.6880Abida W., Cyrta J., Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA. 2019; 116 (23): 11428–36. DOI: 10.1073/pnas.1902651116Abida W., Cyrta J., Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA. 2019; 116 (23): 11428–36. DOI: 10.1073/pnas.1902651116Bluemn E.G., Coleman I.M., Lucas J.M. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF sig- naling. Cancer Cell. 2017; 32 (4): 474–89. DOI: 10.1016/j.ccell.2017.09.003Bluemn E.G., Coleman I.M., Lucas J.M. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF sig- naling. Cancer Cell. 2017; 32 (4): 474–89. DOI: 10.1016/j.ccell.2017.09.003Beltran H., Prandi D., Mosquera J.M. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016; 22 (3): 298–305. DOI: 10.1038/nm.4045Beltran H., Prandi D., Mosquera J.M. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016; 22 (3): 298–305. DOI: 10.1038/nm.4045Zhang Y., Zheng D., Zhou T. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB- EZH2-TSP1 pathway in prostate cancers. Nat. Commun. 2018; 9 (1): 4080. DOI: 10.1038/s41467018061772Zhang Y., Zheng D., Zhou T. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB- EZH2-TSP1 pathway in prostate cancers. Nat. Commun. 2018; 9 (1): 4080. DOI: 10.1038/s41467-018-06177-2Puca L., Vlachostergios P. J., Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med. 2019; 9 (2): 30593. DOI: 10.1101/cshperspect.a030593Puca L., Vlachostergios P. J., Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med. 2019; 9 (2): 30593. DOI: 10.1101/cshperspect.a030593Montironi R., Cimadamore A., Lopez-Beltran A. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells. 2020; 9 (5): 1073. DOI: 10.3390/cells9051073Montironi R., Cimadamore A., Lopez-Beltran A. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells. 2020; 9 (5): 1073. DOI: 10.3390/cells9051073Mahal B.A., Yang D.D., Wang N.Q. et al. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate can- cer. Eur. Urol. 2018; 74 (2): 146–54. DOI: 10.1016/j.eururo.2018.01.043Mahal B.A., Yang D.D., Wang N.Q. et al. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate can- cer. Eur. Urol. 2018; 74 (2): 146–54. DOI: 10.1016/j.eururo.2018.01.043Wang J., Xu W., Mierxiati A. et al. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate. 2019; 79 (13): 1563–71. DOI: 10.1002/pros.23878Wang J., Xu W., Mierxiati A. et al. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate. 2019; 79 (13): 1563–71. DOI: 10.1002/pros.23878Helpap B., Köllermann J., Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol. Int. 1999; 62 (3): 133–8.Helpap B., Köllermann J., Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol. Int. 1999; 62 (3): 133–8.Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al. Prognostic value of serum markers for prostate cancer. Scand. J. Urol. Nephrol. Suppl. 2005; (216): 64–81.Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, et al. Prognostic value of serum markers for prostate cancer. Scand. J. Urol. Nephrol. Suppl. 2005; (216): 64–81.Nadal R., Schweizer M., Kryvenko O.N., Epstein J.I., Eisenberger M.A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 2014; 11 (4): 213–9.Nadal R., Schweizer M., Kryvenko O.N., Epstein J.I., Eisenberger M.A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 2014; 11 (4): 213–9.Conteduca V., Oromendia C., Eng K.W., Bareja R., Sigouros M., Molina A. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer. 2019; 121: 7–18.Conteduca V., Oromendia C., Eng K.W., Bareja R., Sigouros M., Molina A. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer. 2019; 121: 7–18.Apostolidis L., Nientiedt C., Winkler E.C. et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget. 2019; 10 (1): 17–29. DOI: 10.18632/oncotarget.26523Apostolidis L., Nientiedt C., Winkler E.C. et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget. 2019; 10 (1): 17–29. DOI: 10.18632/oncotarget.26523Zhu J., Liang X., Wu D. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine (Baltimore). 2021; 100 (15): 25237. DOI: 10.1097/MD.0000000000025237Zhu J., Liang X., Wu D. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine (Baltimore). 2021; 100 (15): 25237. DOI: 10.1097/MD.0000000000025237Vlachostergios P.J., Papandreou C.N. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol. 2015; 5: 6. DOI: 10.3389/fonc.2015.00006Vlachostergios P.J., Papandreou C.N. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol. 2015; 5: 6. DOI: 10.3389/fonc.2015.00006Papandreou C. N., Daliani D. D., Thall P. F. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J. Clin. Oncol. 2002; 20 (14): 3072–80. DOI: 10.1200/JCO.2002.12.065Papandreou C. N., Daliani D. D., Thall P. F. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J. Clin. Oncol. 2002; 20 (14): 3072–80. DOI: 10.1200/JCO.2002.12.065Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007; 178: 844–8. DOI: 10.1016/j.juro.2007.05.044Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 2007; 178: 844–8. DOI: 10.1016/j.juro.2007.05.044Schaeffer E.M., Srinivas S., Adra N., An Y., Barocas D., Bitting R. et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2023; 21 (10): 1067–96.Schaeffer E.M., Srinivas S., Adra N., An Y., Barocas D., Bitting R. et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2023; 21 (10): 1067–96.Duran I., Berthold D.R., Pond G.R. et al. Meeting: 2007 Prostate Cancer Symposium. Abstract No. 253. Neuroendocrine carcinoma of the prostate: Review of 14 cases at a single institution from 1988–2004.Duran I., Berthold D.R., Pond G.R. et al. Meeting: 2007 Prostate Cancer Symposium. Abstract No. 253. Neuroendocrine carcinoma of the prostate: Review of 14 cases at a single institution from 1988–2004.Stein M., Bernstein Z., Abacioglu U. et al. Small cell (neuroendocrine) carcinomas of the prostate: etiology, diagnosis, prognosis and therapeutic implications – a retrospective study of 30 patients from rare cancer network. Am.J. Med. Scienc. 2008; 336 (6): 478–88.Stein M., Bernstein Z., Abacioglu U. et al. Small cell (neuroendocrine) carcinomas of the prostate: etiology, diagnosis, prognosis and therapeutic implications – a retrospective study of 30 patients from rare cancer network. Am.J. Med. Scienc. 2008; 336 (6): 478–88.Safina S. Z., Isyangulova A. Z. Neuroendocrine prostate cancer. Cancer Urology. 2023;19(2):94–100. (In Russ.) DOI:10.17650/17269776202319294100Safina S. Z., Isyangulova A. Z. Neuroendocrine prostate cancer. Cancer Urology. 2023;19(2):94–100. (In Russ.) DOI:10.17650/1726-9776-2023-19-2-94-100Umar S.A., Maclenna G.T. Small cell carcinoma of the prostate. J. Urol. 2009; 181 (2): 838–9. DOI: 10.1038/nrurol.2014.21Umar S.A., Maclenna G.T. Small cell carcinoma of the prostate. J. Urol. 2009; 181 (2): 838–9. DOI: 10.1038/nrurol.2014.21Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer. 2019; 121: 7–18. DOI: 10.1016/j.ejca.2019.08.011Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur. J. Cancer. 2019; 121: 7–18. DOI: 10.1016/j.ejca.2019.08.011

The authors declare that there are no conflicts of interest present.